Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Czechia

European Research Council grant · Running

LeukemiaBlock Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias

Coordinator
Masarykova univerzita, Czechia
Runs
1 September 2026 to 29 February 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101267309

What the project is doing

In the project's own words, from its summary on CORDIS.

The emergence of therapy resistance and adaptation in acute myeloid leukemia (AML) remains a major challenge, leading to treatment failure and mortality. We and others have provided experimental evidence supporting novel idea that adaptation and resistance to therapy could be in early stages driven by signaling pathway rewiring, rather than genetic mutations. This project aims to advance our novel GAB1 inhibitors, targeting the adaptor protein GAB1- a key regulator of multiple signaling pathways implicated in therapy resistance.

Within our past ERC StG grant “Signaling Propensity in the Microenvironment of B Cell Chronic Lymphocytic Leukemia” (2019–24), we demonstrated that GAB1 inhibition is effective in the single agent format, and also counteracts resistance in various hematologic malignancies, including highly aggressive AML (our US patent 11,648,255B2). Inhibiting GAB1 is particularly challenging due to its role as a docking protein, requiring innovative drug design distinct from conventional kinase inhibitors.

This PoC project has five key objectives: (i) develop and patent a 2nd-generation GAB1 inhibitors, (ii) establish robust biochemical and biological assays for therapeutic evaluation, (iii) identify malignancies responsive to GAB1 inhibition and generate robust pre-clinical data, (iv) elucidate GAB1-mediated signaling modulation in cancer, and (v) assess market potential, formulate a business plan, and secure industry partnerships.

Successful execution will enable further pre-clinical development of this docking protein inhibitor and facilitate clinical translation of our lead compound.

Topics

Who is involved

OrganisationCityCountryRole
Masarykova univerzitaBrnoCzechiaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS